Adelis Equity Partners Acquires Majority Stake in IonOpticks

September 10, 2024

Adelis Equity Partners has taken a majority, controlling stake in IonOpticks, a fast-growing developer and manufacturer of high-performance chromatography solutions for LC‑MS proteomics. The founders and management are co-investors; the investment will fund IonOpticks' global expansion, product development, and support future acquisitions as the company scales its commercial footprint.

Buyers
Adelis Equity Partners
Targets
IonOpticks
Industry
Biotechnology
Location
Victoria, Australia
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.